GeoVax Labs, Inc. has entered into an exclusive worldwide license agreement with Emory University for intellectual property covering the use of Gedeptin in combination with immune checkpoint inhibitors. The licensed technology supports the use of gene-directed enzyme prodrug therapy to enhance the anti-tumor activity of checkpoint blockade, which could potentially convert immunologically 'cold' tumors into more responsive targets.
The exclusive license provides GeoVax with global rights to patent applications and associated know-how covering the combination of Gedeptin with immune checkpoint inhibitors within a defined field of use. This intellectual property estate is intended to support GeoVax's current and planned clinical programs evaluating Gedeptin in combination with ICIs, including its recently announced neoadjuvant strategy in head and neck cancer and ongoing evaluation of additional solid tumor indications.
David A. Dodd, Chairman and Chief Executive Officer of GeoVax, stated that the license further consolidates the company's long-standing relationship with Emory University and meaningfully strengthens its intellectual property position around Gedeptin-based combination therapies. As checkpoint inhibitors continue to move earlier in treatment paradigms, including first-line and neoadjuvant settings, Gedeptin's localized tumor-debulking and immune-sensitizing mechanism may provide an important opportunity to enhance and extend immune checkpoint inhibitor efficacy.
GeoVax has previously reported encouraging clinical and translational data demonstrating that Gedeptin's intratumoral delivery approach can induce localized tumor cell death while promoting immune activation within the tumor microenvironment. This effect may be complementary to systemic checkpoint inhibition, addressing a significant limitation in current cancer immunotherapy approaches. Checkpoint inhibitors have transformed cancer care, but many patients still fail to achieve durable responses.
The company has previously announced plans to evaluate Gedeptin in combination with immune checkpoint inhibitors in a Phase 2 neoadjuvant clinical trial in head and neck squamous cell carcinoma, as well as preclinical assessments in additional solid tumor settings. The Emory license provides a strengthened IP foundation to support these efforts and potential future partnerships. GeoVax continues to evaluate strategic collaboration opportunities related to both the clinical development and potential commercialization of Gedeptin-based combination therapies.
Gedeptin is a gene-directed enzyme prodrug therapy delivered intratumorally using a non-replicating viral vector encoding purine nucleoside phosphorylase. Following administration of a systemically delivered prodrug, the encoded enzyme converts the prodrug into a cytotoxic agent directly within the tumor microenvironment. This localized approach is designed to selectively destroy tumor cells while promoting immune recognition and minimizing systemic toxicity. Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers.
GeoVax's broader pipeline includes the development of GEO-MVA, a Modified Vaccinia Ankara-based vaccine targeting Mpox and smallpox, and GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. The company maintains a global intellectual property portfolio supporting its infectious disease and oncology programs. For more information about the company's development programs, visit https://www.geovax.com.
